Phenotypic and biochemical characterization of the class C β-lactamase, PAC-1
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Otávio Hallal Ferreira Raro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Molecular Microbiology Unit-Department of Oncology, Microbiology, Immunology (OMI), Faculty of Science and Medicine, University of Fribou…. Hauptthemen laut MEDLINE: beta-Lactamases, Pseudomonas aeruginosa, Anti-Bacterial Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Fribourg, NARA, Federal Office of Public Health.
Abstract (Originalsprache)
Background
The class C β-lactamase, PAC-1, was originally described as acquired in Pseudomonas aeruginosa clinical isolates from south Asia, the corresponding gene being chromosomally located and embedded within a Tn1721-like transposon. Despite its association with high-level resistance to cephalosporins and β-lactam/β-lactamase inhibitor combinations, data on its full hydrolytic profile and kinetic parameters have not yet been comprehensively characterized.
Objectives
To characterize the susceptibility profile and hydrolytic kinetics of PAC-1, with a particular focus on cefiderocol hydrolysis, and the activity of novel β-lactam/β-lactamase inhibitor combinations.
Methods
The blaPAC-1 allele was cloned into vector pUCP24 and expressed in Escherichia coli TOP10 and Pseudomonas aeruginosa PAO1, respectively. MICs were determined by broth microdilution and interpreted according to EUCAST guidelines. PAC-1 was purified, and steady-state kinetic measurements of selected β-lactams were determined. IC50 values were determined for the β-lactamase inhibitors avibactam, taniborbactam, xeruborbactam and zidebactam. WGS was performed to characterize the genetic environment of the blaPAC-1 gene.
Results
PAC-1 conferred broad resistance to penicillins, broad-spectrum cephalosporins and cefiderocol, while carbapenems remained unaffected. Kinetic analyses confirmed high catalytic efficiency against cefotaxime and aztreonam, but no hydrolysis of imipenem. Avibactam, relebactam and vaborbactam failed to inhibit PAC-1 (IC50 > 1000 µM), whereas xeruborbactam and zidebactam showed potent inhibitory activities (IC50 = 1.0 and 0.6 µM, respectively). A chromosomally located Tn1721-like transposon was identified carrying the blaPAC-1 gene in P. aeruginosa ST4936.
Conclusions
PAC-1 is not inhibited by avibactam and hydrolyses a broad range of β-lactams including the novel cephalosporin cefiderocol. The combination cefiderocol/zidebactam was the most active against PAC-1. Transposon-mediated dissemination across distinct lineages warrants continued epidemiological surveillance of PAC-type β-lactamases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical and Molecular Microbiology Unit-Department of Oncology, Microbiology, Immunology (OMI), Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, Fribourg CH-1700, Switzerland.
- Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
- Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
- SIB Swiss Institute of Bioinformatics, Zurich, Switzerland.
- Department of Microbiology, The University of Haripur, Haripur, Pakistan.
ORCID-Profile: Otávio Hallal Ferreira Raro, Jacqueline Findlay, Adrian Egli, Patrice Nordmann, Laurent Poirel
Förderung
- University of Fribourg
- NARA
- Federal Office of Public Health
Zitieren
APA
Raro, O. H. F., Mancini, S., Findlay, J., Seth-Smith, H. M. B., Ali Syed, M., Egli, A., Nordmann, P., & Poirel, L. (2026). Phenotypic and biochemical characterization of the class C β-lactamase, PAC-1. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag291
Vancouver
Raro OHF, Mancini S, Findlay J, Seth-Smith HMB, Ali Syed M, Egli A, et al. Phenotypic and biochemical characterization of the class C β-lactamase, PAC-1. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag291
BibTeX
@article{Raro2026,
author = {Raro, Otávio Hallal Ferreira and Mancini, Stefano and Findlay, Jacqueline and Seth-Smith, Helena M B and Ali Syed, Muhammad and Egli, Adrian and Nordmann, Patrice and Poirel, Laurent},
title = {Phenotypic and biochemical characterization of the class C β-lactamase, PAC-1},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag291}
}
EUVIMED